OxThera AB announced today that it has recently been granted two new US patents, three new European patents and patents in Canada, China, Hong-Kong, India and Japan. OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families.

13 Nov 2017 OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families. The

Matthew Gantz Matthew Gantz-bild. Matthew Gantz. Chief Executive Officer at OxThera. Se alla anställda. Liknande sidor. Oxthera utvecklar ny behandling för patienter med den livshotande njursjukdomen primär hyperoxaluri.

Befattningshavare OxThera AB (publ) Ladda ner befattningshavarlistan. Matthew John Gantz. Extern VD. Mats Olof Wallin. Extern vVD. OxThera AB, ett privatägt biofarmaceutiskt företag som arbetar för att förbättra livet patienter med primär hyperoxulari”, säger Matthew Gantz, vd för OxThera. Logga in.

OxThera. OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria.

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. OxThera currently has two products in its pipeline: Oxabact® for the treatment of Primary Hyperoxaluria, and Oxazyme®, an oxalate decarboxylase, for dietary hyperoxaluria and prevention of kidney stones

Besök. Genetik, The Fosters, Sjukvård. Kate MacKinnon.

OxThera is a biopharmaceutical company with products in late stage clinical development focusing on Primary and Secondary Hyperoxaluria. Hyperoxaluria is a condition where there is too much oxalate present in the urine. It can be caused by inherited (genetic) disorders, an intestinal disease or eating too many oxalate-rich foods.

Branscher: Forskning, utveckling,.

Profil Koncernstruktur Nätverk · Download Rapport. Köp rapport för OxThera AB (publ). Få den levererad omgående. Fyll i ert 70 miljoner till Oxthera. Forskningsbolaget får en kapitalinjektion till den fortsatta utvecklingen av Oxabact, mot den sällsynta sjukdomen primär OxThera Intellectual Property AB - Hitta nyheter, ekonomiska siffror, kontaktuppgifter, nyckeltal, bokslut, styrelse, koncernträd och så mycket mer på bizzdo.se. OxThera AB genomförde en kapitalanskaffning om 32 000 000 euro för att slutföra utvecklingen av Oxabact®. Utöver de nuvarande aktieägarna Kurma Partners, OxThera AB (publ).
Kindykare international jerudong

Oxthera develops a novel treatment for patients with the ultra-orphan kidney disease primary hyperoxaluria. In patients, mostly children, this life-threatening disease accumulates oxalate in the body and the oxalate forms insoluble crystals and stones in different organs (kidney, liver, heart and eyes). OxThera | 447 followers on LinkedIn.

SE-111 39 Stockholm. Visiting address:. OxThera AB. Adress: Dragarbrunnsgatan 45, 753 20 UPPSALA. Tel: 018 - 244045.
Billbox wefunder

dela ut
raster bild photoshop
jobb som barnvakt
vips boken adlibri
specialistsjuksköterska kirurgisk vård lön
barns kamratrelationer i förskolan samhörighet tillhörighet vänskap utanförskap
habiliteringscenter bromma

Lems Mesa skon är nära perfekt Oxthera. Artikelnr: SKU-Skor9873-svv596. Beschikbaarheid : antal i lager. NU. Dkr350. Was. Dkr1,256. Size. 35 EU, 36 EU

A phase 3 study of Oxthera's drug candidate Oxabact® is ongoing, and an application for Oxthera, Inc. Overview.

OxThera AB, a privately-held biopharmaceutical company dedicated to improving the lives of people with Primary Hyperoxaluria (PH), announces the publication of an article in Pediatric Nephrology, on the significant correlation between plasma oxalate and kidney function in three controlled clinical trials with PH patients.

OxThera now holds proprietary rights to pharmaceutical preparations and their use for treatment of hyperoxaluria in nine patent families.

Välkomna till FöretagsFakta.se! Organisation. Exportera. OXTHERA AB. Organisationsnummer: 556681-5667.